fevarin õhukese polümeerikattega tablett
viatris sia - fluvoksamiin - õhukese polümeerikattega tablett - 100mg 30tk; 100mg 50tk
esomeprazole hospira süste-/infusioonilahuse pulber
hospira uk limited - esomeprasool - süste-/infusioonilahuse pulber - 40mg 10tk; 40mg 1tk; 40mg 25tk; 40mg 5tk
gingium 120mg õhukese polümeerikattega tablett
sandoz pharmaceuticals d.d. - hõlmikpuulehed - õhukese polümeerikattega tablett - 120mg 30tk; 120mg 100tk
telmisartan-ratiopharm 80mg tablett
ratiopharm gmbh - telmisartaan - tablett - 80mg 50tk; 80mg 84tk; 80mg 10tk; 80mg 90tk; 80mg 56tk; 80mg 7tk; 80mg 14tk; 80mg 30tk; 80mg 98tk; 80mg 100tk
zenicamo tablett
zentiva k.s. - kandesartaan+amlodipiin - tablett - 8mg+5mg 84tk; 8mg+5mg 28tk; 8mg+5mg 14tk; 8mg+5mg 56tk; 8mg+5mg 98tk; 8mg+5mg 30tk; 8mg+5mg 90tk
sitagliptin/metformin hydrochloride sandoz gmbh õhukese polümeerikattega tablett
sandoz pharmaceuticals d.d. - metformiin+sitagliptiin - õhukese polümeerikattega tablett - 1000mg+50mg 100tk; 1000mg+50mg 180tk; 1000mg+50mg 168tk; 1000mg+50mg 7tk; 1000mg+50mg 50tk; 1000mg+50mg 28tk
perindopril krka tablett
krka d.d. novo mesto - perindopriil - tablett - 2mg 50tk; 2mg 14tk; 2mg 60tk; 2mg 28tk; 2mg 90tk; 2mg 100tk; 2mg 7tk
varilrix süstelahuse pulber ja lahusti
glaxosmithkline biologicals - tuulerõugete viirus, elus, nõrgestatud - süstelahuse pulber ja lahusti - 1annus 10tk
comirnaty
biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaktsiinid - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. kasutamist see vaktsiin peaks olema kooskõlas ametlike soovitustega.
elocta
swedish orphan biovitrum ab (publ) - sama loomulikku protsessi lüsosomaalse - hemofiilia a. - antihemorraagilised ained - verejooksu ravi ja profülaktika hemofiilia a patsientidel (kaasasündinud viii faktori puudulikkus). elocta võib kasutada kõikides vanuserühmades.